Last €120.03 EUR
Change Today -0.97 / -0.80%
Volume 10.0
XP2 On Other Exchanges
As of 3:30 AM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

salix pharmaceuticals ltd (XP2) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/26/14 - €121.00
52 Week Low
09/26/13 - €48.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

salix pharmaceuticals ltd (XP2) Related Businessweek News

No Related Businessweek News Found

salix pharmaceuticals ltd (XP2) Details

Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases in the United States. The company provides XIFAXAN tablets to treat overt hepatic encephalopathy, and patients with travelers’ diarrhea; APRISO too maintain remission of ulcerative colitis (UC); MOVIPREP and OSMOPREP for cleansing of the colon as a preparation for colonoscopy in adults; RELISTOR for the treatment of opioid-induced constipation (OIC) in patients with advanced illness; SOLESTA to treat fecal incontinence; and DEFLUX to treat vesicoureteral reflux. It also offers FULYZAQ for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy; GIAZO, COLAZAL, and UCERIS to treat mildly to moderately active UC; and METOZOLV ODT for the treatment of refractory gastroesophageal reflux disease (GERD) that fails to respond to conventional therapy. Its products also comprise AZASAN azathioprine tablets, which are used as adjunct to prevent rejection in renal homotransplantations and to reduce signs and symptoms of severe active rheumatoid arthritis; ANUSOL-HC and PROCTOCORT for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and PEPCID for the short-term treatment of GERD, active duodenal ulcer, active benign gastric ulcer, erosive esophagitis due to GERD, and peptic ulcer diseases. In addition, the company provides DIURIL to treat hypertension and also as adjunctive therapy; ZEGERID for the treatment of upper gastrointestinal conditions; GLUMETZA and CYCLOSET to enhance glycemic control in adults with type 2 diabetes mellitus; and FENOGLIDE to treat lipoprotein-cholesterol, total cholesterol, triglycerides, and apolipoprotein B, as well as hypertriglyceridemia. It has strategic collaboration with RedHill Biopharma Ltd. Salix Pharmaceuticals, Ltd. was founded in 1989 and is headquartered in Raleigh, North Carolina.

Founded in 1989

salix pharmaceuticals ltd (XP2) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $867.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $488.9K
Chief Development Officer, Chief Medical Offi...
Total Annual Compensation: $466.4K
Executive Vice President of Business Developm...
Total Annual Compensation: $437.0K
Compensation as of Fiscal Year 2013.

salix pharmaceuticals ltd (XP2) Key Developments

Allergan Reportedly Approached Salix For Acquisitions

Allergan Inc. (NYSE:AGN) has reportedly approached Salix Pharmaceuticals Ltd. (NasdaqGS:SLXP) and at least one other company about a potential acquisition, as Allergan seeks to fend off a $53-billion hostile takeover from Valeant Pharmaceuticals International, Inc. (TSX:VRX). Allergan could strike a takeover deal with the company or another unknown party as early as next month, September 2014. Allergan has said it is eyeing acquisitions of its own.

Levi & Korsinsky Notifies Investors of Salix Pharmaceuticals Ltd. of Class Action Against its Board Of Directors in Connection with the Sale Of the Company to Cosmo Tech

Levi & Korsinsky notified to the investors of Salix Pharmaceuticals Ltd. of claims of breaches of fiduciary duty and other violations of state law in connection with the sale of the company to Cosmo Tech, a subsidiary of Cosmo Pharmaceuticals S.p. A which will change its name to Salix Pharmaceuticals, plc upon the completion of the merger. A complaint was filed in Delaware state court. Under the terms of the transaction, Salix shareholders will receive one share of the post-merger entity for each share of Salix they own. Salix shareholders will own 80% of the newly combined company. The claims concern whether the Board of Salix breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Cosmo Pharmaceuticals S.p.A. is underpaying for Salix shares.

Salix Pharmaceuticals Ltd. Announces Results for Microbiome, Culture & Susceptibility

Salix Pharmaceuticals Ltd. announced the from the analysis of the microbiome, culture and susceptibility, and two key secondary efficacy endpoints from data collected in TARGET 3 - a Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeat treatment with rifaximin 550 mg TID (three times daily) for 14 days in subjects with irritable bowel syndrome with diarrhea, or IBS-D, who respond to an initial treatment course with rifaximin 550 mg TID for 14 days. The effects of rifaximin on the gut microbiota in the IBS-D repeat treatment study, TARGET 3, were evaluated by two methods: traditional culture techniques and next-generation gene sequencing of stool samples collected from approximately 100 randomly selected subjects in the trial. Skin swabs were also obtained from an additional 113 randomly selected subjects and cultured for Staphylococcus bacteria. Using next-generation 16S rRNA gene sequencing methods, the company generated approximately 2.2 billion base pairs from stool samples collected over the course of the study from approximately 100 randomly selected subjects.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XP2:GR €120.03 EUR -0.97

XP2 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for XP2.
View Industry Companies

Industry Analysis


Industry Average

Valuation XP2 Industry Range
No financial data is available for XP2.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SALIX PHARMACEUTICALS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at